LNC Therapeutics becomes YSOPIA Bioscience marking its transition to a clinical stage company

• YSOPIA Bioscience received approval in early September 2020 of its clinical trial application (IND) to launch a Phase 1 trial in obesity and associated metabolic diseases

• 4 development programs for innovative drugs candidates based on the potential of key bacteria of the gut microbiome in human health

• YSOPIA Bioscience will carry on the development of its Live Biotherapeutics Products (LBP), a new class of drugs targeting chronic diseases with high unmet medical needs

Bordeaux, France, September 29^th, 2020 – LNC Therapeutics, a French biotech company harnessing the properties of keystone single-strain bacteria to develop ground-breaking microbiome-based drugs, announced today changing its name to YSOPIA Bioscience.

Founded in 2010 to address the root causes of obesity and associated metabolic disorders, the Company quickly centered its Research & Development activities on the promising path of the gut microbiome.

Since 2018, the Company has been focusing on the development of a portfolio of innovative drugs derived from the microbiome using the unique properties of single strain bacteria. YSOPIA Bioscience targets more specifically a group of keystone bacteria essential to human health: christensenella. The Company is also extending its field of application to several other chronic indications with a strong need for breakthrough therapeutic innovations.

Following the recent approval by the U.S. FDA of its clinical trial application (IND) in obesity and associated metabolic diseases, this name change marks YSOPIA Bioscience’s development strategy and its transition to a clinical stage biotechnology company.

“This new name, YSOPIA Bioscience, symbolizes the major success of our teams in advancing to the clinic, in line with our ambition to become a major player in therapies based on the gut microbiome properties. We are now on the edge of beginning the studies that will evaluate the therapeutic potential of our technology. Above all, we strive to demonstrate the efficacy of Christensenella bacteria in human health in order to offer, as soon as possible, a therapeutic solution to patients suffering from chronic pathologies, for which there is currently no effective treatment,“ commented Dr. Georges Rawadi, CEO of YSOPIA Bioscience.

The meaning of YSOPIA:

This new name was inspired by Ancient Greece, a time when many of the fundamentals of modern medicine were born. In particular, it refers to Epione, the goddess soothing pain in Greek mythology. In addition, YSOPIA is inspired by the Greek word for balance, an essential characteristic of a healthy intestinal microbiome, which contributes to its proper functioning and positive impact on human health.

About Live Biotherapeutic Products (LBPs):

According to the US Food and Drug Administration, a live biotherapeutic product contains live organisms, such as bacteria, and is applicable to the prevention, treatment, or cure of a disease or condition in human beings. YSOPIA Bioscience has opted to develop single strain live biotherapeutic products, which use a single strain of bacteria selected specifically for each drug candidate.

YSOPIA Bioscience is currently conducting 4 drug candidate development programs:

• Yso1, evaluating the therapeutic potential of Xla1, YSOPIA Bioscience’s first Live Biotherapeutic Product dedicated to the treatment of obesity and associated metabolic disorders. This program has recently obtained approval from the U.S. FDA to initiate a Phase 1 clinical trial in humans.
• Yso2 et Yso3, in collaboration with the Micalis Institute, dedicated to the development of new Live Biotherapeutic Products for the treatment of inflammatory diseases, including IBD.
• Yso4, aiming to develop a Live Biotherapeutic Product for the treatment of mood disorders. YSOPIA Bioscience also has an exclusive license on the patent from the University of Valencia regarding the therapeutic applications of Christensenella bacteria in these indications.

Contacts
NewCap, Press Relations
Arthur Rouillé
arouille@newcap.fr

YSOPIA Bioscience, Corporate Communication
Caroline Bernard
caroline.bernard@ysopia.bio